AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04239118 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Complex endoscopic treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets
Description: Complex endoscopic bleeding ulcers treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets
Study NCT04239118 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional methods of endoscopic hemostasis
Description: Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents
Study NCT02773199 — intervention group
Intervention type: OTHER
Intervention: Preoperative Fasting for 8 hours
Description: Patients will be exposed to preoperative fasting
Study NCT02773199 — intervention group
Intervention type: OTHER
Intervention: Preoperative Fasting for more than 12 hours
Description: Patients will be exposed to preoperative fasting
Study NCT02773199 — intervention group
Intervention type: DRUG
Intervention: Spinal Anesthesia with Bupivacaine
Description: Spinal Anesthesia with heavy bupivacaine 0.5% is provided.
Study NCT02171390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone 250mg injection
Description: The testosterone 250mg ester intramuscular injections performed in three weeks
Study NCT02171390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosteron 50 mg transdermal gel
Description: 50mg testosterone gel implemented on every night
Study NCT02678871 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)
Description: Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)
Study NCT02678871 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: WATCHMAN
Description: LAA closure with the WATCHMAN device
Study NCT02056470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom Total Knee
Description: The Freedom Total Knee System is being implanted in subjects suitable for a total knee replacement
Study NCT02056470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement
Description: total Knee replacement implant
Study NCT02056470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom Total Knee System
Description: Total Knee replacement implant
Study NCT02841748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg, every three weeks, iv, x 1 year
Study NCT02841748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: iv, every three weeks, x 1 year
Study NCT00359632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zyvox - linezolid
Description: Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.
Study NCT00359632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched control
Description: Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit. The control group had only a baseline visit and there were no post baseline study visits.
Study NCT01088919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral tablet
Study NCT00304135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT02391350 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and re-assurance
Description: Patients are provided the Back Book and the contents are reviewed emphasizing the favorable natural history of back pain and sciatica and the importance of remaining active.
Study NCT02391350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy will consist of repeated exercises, spinal mobilization and mechanical traction in an effort to maximize centralization of symptoms.
Study NCT02517151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Study NCT02517151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01012505 — intervention group
Intervention type: OTHER
Intervention: adding pad with maternal milk in hte incubator
Description: 2 days prior to intervention - recording infants data and taking saliva cortisol adding pad with maternal milk - during 2 days - recording infants data and taking saliva cortisol.~stopping intervention and for other 2 days recording infants data and taking saliva cortisol
Study NCT00304135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT01088919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone hydrochloride
Description: oral tablet
Study NCT02192606 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Storz 3D Laparoscopy System
Description: The Storz 3D Laparoscopy System is a new device that allows for laparoscopic surgeons to utilize 3D imaging during surgery with a fraction of the cost of the da Vinci Surgical System, a three-dimensional visual system.
Study NCT02192606 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D Laparoscopy
Description: The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy.
Study NCT02207972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of Ultrasound
Description: The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
Study NCT02207972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No ultrasound used
Description: Palpation of anatomical landmarks is used for placement of labor analgesia
Study NCT03490357 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control - Transversus Abdominus Plane Block
Description: Abdominal fascial plane block - regional anesthesia
Study NCT03490357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: Abdominal fascial plane block - regional anesthesia
Study NCT00553683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00553683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poly ICLC
Study NCT00553683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic artery embolization
Study NCT00553683 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT02482441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-131R10
Description: There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.
Study NCT02482441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
Study NCT02068131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novaferon
Description: Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times per week for first 2 weeks, followed by 20μg,im, 3 times per week after 2 weeks.
Study NCT02068131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).
Study NCT05989035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal subcutaneous adipose tissue biopsy
Description: Fatty tissue biopsy- Participant will be placed in a supine position with arms placed at side while abdominal skin is marked with a skin marker and cleansed with chlorhexidine. Afterwards, the abdominal fatty tissue biopsy will be performed.~Collect fatty tissue from young and older individuals and gather data on the effect of methionine aminopeptidase protein (MetAP2) inhibition on that fatty tissue in the laboratory.
Study NCT05989035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal subcutaneous adipose tissue biopsy
Description: Fatty tissue biopsy- Participant will be placed in a supine position with arms placed at side while abdominal skin is marked with a skin marker and cleansed with chlorhexidine. Afterwards, the abdominal fatty tissue biopsy will be performed.~Collect fatty tissue from young and older individuals and gather data on the effect of methionine aminopeptidase protein (MetAP2) inhibition on that fatty tissue in the laboratory.
Study NCT01714752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: measure of left ventricular and diastolic pressure at exercise
Study NCT01325324 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: measurement of intraocular pressure
Description: Intraocular pressure will be measured with the following devices (each 2 times)at the first and only study visit
Study NCT00794092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinerem administration
Description: Single dose
Study NCT00859833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes).
Study NCT00859833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Myocardial perfusion reserve measured during regadenoson (0.4 mg/5 ml) bolus administration using quantitative perfusion MRI.
Study NCT04281342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg
Description: Repeated administration of a 25 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
Study NCT04281342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 100 mg
Description: Repeated administration of a 100 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
Study NCT04281342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 10, followed by 18 days of observation.
Study NCT04281342 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Moxifloxacin control to establish assay sensitivity
Description: Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 9. On Day 10, oral administration of one single 400 mg moxifloxacin tablet open-label, followed by 18 days of observation.
Study NCT01463527 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nellcor NPB-70 Capnograph
Description: Use of capnography as an additional monitor during sedation to detect hypoventilation and apnea prior to declines in pulse oximetry and clinical examination findings
Study NCT03038243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)
Description: 2.25 x 10\^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56
Study NCT01463527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nellcor NPB-70 Capnograph
Description: Use of capnography as an additional monitor during sedation to detect hypoventilation and apnea prior to declines in pulse oximetry and clinical examination findings
Study NCT01088503 — intervention group
Intervention type: DRUG
Intervention: ADP receptor inhibitors
Description: Dosage regimen as determined by the treating physician.
Study NCT02943694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TaTME with CS-Compact (GelPoint pathway)
Description: Standard TaTME with circular stapler (Short and straight, CS Compact), designed for extra-corporeal and endo-anal anastomosis procedures.
Study NCT03259295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digiclamp (Skin tag removal initial plus follow-up)
Description: Skin tag will be assessed for size, location, and overall appearance. After assessment and confirmation that the skin tag is not infected or possibly malignant, the site will be photographed, prepped with an antimicrobial solution, anesthetized, and removed using the Digiclamp. A bandaid will be applied to the site. Site of skin tag removal will be photographed to document lesion recurrence and presence of scar tissue or hyperpigmentation. Subjects will be asked to complete a brief survey about their satisfaction with the use of Digiclamp.
Study NCT03892317 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pharmacist led medication adherence interventions
Description: Medication adherence interventions which will be tailored to individual patient need
Study NCT03038243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella flexneri 2a whole cell (Sf2aWC) vaccine
Description: 2.25 x 10\^11 Sf2WC cells administered orally on Days 0, 28, and 56
Study NCT03038243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
Study NCT02046525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous fecal microbiota therapy
Study NCT02046525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline enema
Study NCT00733369 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PFC Sigma RP-F
Description: An orthopaedic implant for total knee replacement with a high flexion rotating platform bearing
Study NCT00733369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC Sigma RP
Description: An orthopaedic implant for total knee replacement with a standard flexion rotating platform bearing
Study NCT03528473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention consists of 60 minutes sessions, divided into 40 minutes of aerobic exercise and 20 minutes of circuit training for muscular strength and flexibility exercises.~Aerobic exercise is performed using treadmill, exercise bikes, syncro and arm-ergometers, gradually increasing the exercise intensity, after a 10 minutes period of warming-up, to 60-80 % of Maximum Heart Rate.~Resistance training consists of resistance exercises for large muscle groups, performed with body weight-exercises and isotonic machines.
Study NCT04531657 — intervention group
Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly during 2008-2009 season for measurement of A/Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Florida/4/2006-like antigens
Study NCT03463993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: TXA (10mg/kg) solution for injection from the vial will be diluted with 100 - 200ml electrolyte solution such as Normal Saline, Ringers solution, dextrose/water for injection on the same day it is to be used (i.e. when anaesthetist notes the patient has been randomized to receive TXA). Intravenous administration should be at a rate of 100mg or fraction thereof over at least 1 minute - usually at least 5 minutes. Standard practice is to administer over 20 minutes. Administration is to be done at least 10 minutes prior to skin incision.
Study NCT03463993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.
Study NCT03463993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.
Study NCT03425487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based Intervention
Description: MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
Study NCT03425487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion based Intervention
Description: ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
Study NCT03425487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Usual specialized treatment in mental health (psychological or/and psychiatric)
Study NCT02714933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI sequence Advanced ZTE
Description: Evaluation of the image quality in terms of visualization of anatomical structures of the lung parenchyma in safe zone by a new imaging method of the pulmonary parenchyma by MRI (Advanced ZTE sequence).
Study NCT02972502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Patients receive 10 mg of intravenous (IV) metoclopramide.
Study NCT01149395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dosage: 30 mg once per day for 4 weeks by mouth
Study NCT02972502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Patients receive 2.5 mg of IV haloperidol.
Study NCT02972502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: All patients receive a 1-liter bolus of normal saline (NS)
Study NCT02972502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: All patients receive a 1-liter bolus of normal saline (NS)
Study NCT02972502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: All patients receive 25 mg of intravenous (IV) diphenhydramine.
Study NCT02972502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: All patients receive 25 mg of intravenous (IV) diphenhydramine.
Study NCT02668848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water
Description: If USG>1.02, patients will be advised to drink water via oral or tubal feeding with a dose of 5cc/kg body weight , maximum 300cc, and repeat the same amount of water after dinner in the same day.
Study NCT01763918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT03296865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: We applied a hypoallergenic, porous and adhesive tape of cotton (Kinesio Tex Gold) placed over Rectus Femoris muscle of the affected limb. Children were taped in accordance to Kenzo Kase's Kinesio manual. We used a facilitation technique, from muscle origin to insertion, in a Y shape. For KT condition: base of the KT strip 3cm below the anterior iliac spine, over the RF muscle until the upper edge of the patella and stretchered with 100% tension. For placebo condition: same technique without tension in the entire tape.~We verified the immediate effect of KT/placebo. After the evaluation, KT/placebo was removed.
Study NCT03181867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: Subjects will receive IV dose of 18F-DCFPyL by bolus injection. The maximum amount of injected active drug will be less than 4.02 mcg. The target administered activity will be 8 mCi.
Study NCT03296865 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio taping
Description: We applied a hypoallergenic, porous and adhesive tape of cotton (Kinesio Tex Gold) placed over Rectus Femoris muscle of the affected limb. Children were taped in accordance to Kenzo Kase's Kinesio manual. We used a facilitation technique, from muscle origin to insertion, in a Y shape. For KT condition: base of the KT strip 3cm below the anterior iliac spine, over the RF muscle until the upper edge of the patella and stretchered with 100% tension. For placebo condition: same technique without tension in the entire tape.~We verified the immediate effect of KT/placebo. After the evaluation, KT/placebo was removed.
Study NCT01377428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
Study NCT02703831 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Single Attending
Description: One spine attending and an assistant perform surgery. The assistant can be a spine fellow, a resident or a physician's assistant.
Study NCT04208633 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Horizontal placement of the intraocular lens in the capsular bag
Description: The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.